NDA 212035 · Accord Hlthcare
Argatroban In Sodium Chloride
Argatroban · Intravenous · Anti-coagulant; Direct Thrombin Inhibitor
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 7, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
5 Phase 3, 1 recruiting
FAERS reports
1,499
1,309 serious, 321 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 21, 2026.
Argatroban in Sodium Chloride injection is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) ( 1.1 ) As an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI) ( 1.2 ) 1.1 Heparin-Induced Thrombocytopenia Argatroban in Sodium Chloride Injection is indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT). 1.2 Percutaneous Coronary Intervention Argatroban in Sodium Chloride Injection is indicated as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI).
Mechanism: Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or –induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation. Argatroban inhibits thrombin with an inhibition constant (K i ) of 0.04 μM. At therapeutic concentrations, argatroban has little or no effect on related serine proteases (trypsin, factor...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ARGATROBAN IN SODIUM CHLORIDE · ARGATROBAN 50MG/50ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Argatroban" as an intervention, any sponsor and status, largest first.
- Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic StrokePivotal-lookingCompleted
Combination Therapy for Acute Ischemic Stroke Study GroupAcademic, hospital or other
NCT00153946 · 814 participants · Start Aug 2004 · Primary completion Mar 2008
Drug: Edaravone · For: Stroke
Sites: Suita, Japan
- Argatroban Plus R-tPA for Acute Ischemic StrokePivotal-lookingCompleted
General Hospital of Shenyang Military RegionAcademic, hospital or other
NCT03740958 · 808 participants · Start Dec 21, 2018 · Primary completion Jan 30, 2022
Drug: rt-PA; Argatroban · For: Stroke
Sites: Shenyang, China
- Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)Pivotal-lookingCompleted
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT04275180 · 628 participants · Start Mar 21, 2020 · Primary completion Jul 31, 2022
Drug: Argatroban · For: Acute Progressive Ischemic Stroke
Sites: Hangzhou, China; Anji, China; Jiaxing, China · 6 sites in all
- Multi-arm Optimization of Stroke ThrombolysisPivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT03735979 · 514 participants · Start Oct 15, 2019 · Primary completion Dec 1, 2023
Drug: Argatroban; Eptifibatide and 1 more · For: Acute Ischemic Stroke
Sites: Birmingham, Alabama; Fullerton, California; La Jolla, California · 61 sites in all
- Thromboprophylaxis After Surgery for Gynecologic Malignancy in ChinaPivotal-lookingCompleted
Huazhong University of Science and TechnologyAcademic, hospital or other
NCT02935530 · 315 participants · Start Jan 2016 · Primary completion Aug 2017
Drug: s-LMWH; LMWH and 1 more · For: Gynecologic Neoplasms; Venous Thromboembolism; Low Molecular Weight Heparin and 1 more
Sites: Wuhan, China
- Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMONot yet recruiting
University Hospital OstravaAcademic, hospital or other
NCT07499037 · 200 participants (planned) · Start Jan 2027 · Primary completion Sep 2029
Drug: Low anticoagulation dose of argatroban and enoxaparin during ECMO; Standard anticoagulation dose of argatroban and enoxaparin during ECMO · For: Pneumonia; Heart Failure
Sites: Ostrava, Czechia; Prague, Czechia
- Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)Pivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00508924 · 140 participants · Start Aug 2005
Drug: Argatroban; Argatroban and 2 more · For: Coronary Artery Disease; Angina, Unstable
Sites: Aalst, Belgium; Bad Nauheim, Germany; Cologne, Germany · 8 sites in all
General Hospital of Shenyang Military RegionAcademic, hospital or other
NCT03552354 · 120 participants · Start Oct 25, 2017 · Primary completion Oct 8, 2018
Drug: Argatroban plus dual antiplatelet · For: Stroke, Ischemic
Sites: Shenyang, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- heparin-induced thrombocytopenia191
- drug ineffective157
- international normalised ratio increased110
- off label use99
- activated partial thromboplastin time prolonged83
- haemorrhage81
- pulmonary embolism70
- thrombocytopenia70
- deep vein thrombosis69
- coagulation time prolonged64
- thrombosis56
- gastrointestinal haemorrhage54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 22 |
| 2006 | 42 |
| 2007 | 64 |
| 2008 | 48 |
| 2009 | 47 |
| 2010 | 195 |
| 2011 | 99 |
| 2012 | 74 |
| 2013 | 39 |
| 2014 | 43 |
| 2015 | 47 |
| 2016 | 32 |
| 2017 | 68 |
| 2018 | 53 |
| 2019 | 87 |
| 2020 | 86 |
| 2021 | 94 |
| 2022 | 92 |
| 2023 | 69 |
| 2024 | 61 |
| 2025 | 83 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke.
Adeoye O, Broderick J, Derdeyn CP, et al. · N Engl J Med 2024 · Adaptive Clinical Trial, Clinical Trial, Phase III
- Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia.
Nilius H, Kaufmann J, Cuker A, et al. · Am J Hematol 2021 · Comparative Study, Meta-Analysis
- Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
Chen HS, Cui Y, Zhou ZH, et al. · JAMA 2023 · Randomized Controlled Trial, Multicenter Study
- Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial.
Xu J, Liu Y, Wang H, et al. · Stroke 2025 · Randomized Controlled Trial, Multicenter Study
- Effects of argatroban therapy for stroke patients: A meta-analysis.
Hou X, Jin C, Pan C, et al. · J Clin Neurosci 2021 · Meta-Analysis, Review
- Can the combination of antiplatelet or alteplase thrombolytic therapy with argatroban benefit patients suffering from acute stroke? a systematic review, meta-analysis, and meta-regression.
Xie H, Chen Y, Ge W, et al. · PLoS One 2024 · Meta-Analysis, Systematic Review
Sponsor: Accord Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.